78,726 Boston Scientific Corporation $BSX Shares Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 164.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 126,489 shares of the medical equipment provider’s stock after buying an additional 78,726 shares during the period. Fulcrum Asset Management LLP’s holdings in Boston Scientific were worth $5,550,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. StoneRidge PMG Advisors LLC bought a new stake in Boston Scientific in the 3rd quarter valued at $638,000. Hohimer Wealth Management LLC bought a new position in Boston Scientific during the 3rd quarter worth $4,266,000. Brighton Jones LLC increased its position in Boston Scientific by 45.8% during the 3rd quarter. Brighton Jones LLC now owns 80,361 shares of the medical equipment provider’s stock worth $3,508,000 after buying an additional 25,252 shares during the period. Candriam S.C.A. increased its position in Boston Scientific by 17.1% during the 3rd quarter. Candriam S.C.A. now owns 430,284 shares of the medical equipment provider’s stock worth $18,851,000 after buying an additional 62,799 shares during the period. Finally, Ethic Inc. lifted its holdings in shares of Boston Scientific by 11.1% during the third quarter. Ethic Inc. now owns 232,231 shares of the medical equipment provider’s stock worth $10,137,000 after buying an additional 23,294 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $70.00 to $52.00 and set an “outperform” rating for the company in a research report on Thursday, October 29th. TD Cowen cut shares of Boston Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $56.00 to $46.00 in a research note on Friday, October 30th. Citigroup cut their price objective on shares of Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, October 29th. Truist Financial decreased their target price on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, October 14th. Finally, Barclays lowered their target price on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $61.43.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $44.00 on Tuesday. Boston Scientific Corporation has a 1 year low of $39.57 and a 1 year high of $105.65. The stock has a market capitalization of $63.78 billion, a price-to-earnings ratio of 18.64, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.74. The company’s 50 day simple moving average is $44.26 and its 200 day simple moving average is $55.46.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the prior year, the company earned $0.75 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. As a group, research analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world.